Cargando…

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus

Recombinant poxviruses, utilized as vaccine vectors and oncolytic viruses, often require manipulation at multiple genetic loci in the viral genome. It is essential for viral vectors to possess no adventitious mutations and no (antibiotic) selection marker in the final product for human patients in o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Zong Sheng, Liu, Zuqiang, Sathaiah, Magesh, Wang, Jiahu, Ravindranathan, Roshni, Kim, Eun, Huang, Shaohua, Kenniston, Thomas W., Bell, John C., Zeh, Herbert J., Butterfield, Lisa H., Gambotto, Andrea, Bartlett, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651493/ https://www.ncbi.nlm.nih.gov/pubmed/29085848 http://dx.doi.org/10.1016/j.omtm.2017.09.007

Ejemplares similares

Oncolytic viruses as therapeutic cancer vaccines
por: Bartlett, David L, et al.
Publicado: (2013)

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
por: Francis, Lily, et al.
Publicado: (2016)

Oncolytic Poxvirus Armed with Fas Ligand Leads to Induction of Cellular Fas Receptor and Selective Viral Replication in FasR Negative Cancer
por: Sathaiah, Magesh, et al.
Publicado: (2011)

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2015)

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2017)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
por: Downs-Canner, Stephanie, et al.
Publicado: (2016)

The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host
por: Guo, Z. Sheng, et al.
Publicado: (2010)

TRAIL Gene-Armed Oncolytic Poxvirus and Oxaliplatin Can Work Synergistically against Colorectal Cancer
por: Ziauddin, Mohammed F, et al.
Publicado: (2010)

A cautionary note on the selectivity of oncolytic poxviruses
por: Tang, Bingtao, et al.
Publicado: (2019)

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
por: Guo, Zong Sheng, et al.
Publicado: (2019)

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
por: Ricordel, Marine, et al.
Publicado: (2018)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
por: Ge, Yan, et al.
Publicado: (2020)

IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity
por: Yang, Min, et al.
Publicado: (2021)

Oncolytic Virus Promotes Tumor-Reactive Infiltrating Lymphocytes for Adoptive Cell Therapy
por: Feist, Mathilde, et al.
Publicado: (2021)

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
por: Guo, Zong Sheng, et al.
Publicado: (2014)

Cowpox Virus: A New and Armed Oncolytic Poxvirus
por: Ricordel, Marine, et al.
Publicado: (2017)

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
por: Parato, Kelley A, et al.
Publicado: (2012)

Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice
por: Khan, Muhammad S., et al.
Publicado: (2023)

Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus
por: Cho, Euna, et al.
Publicado: (2018)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation
por: Kim, Eun, et al.
Publicado: (2016)

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2
por: Liu, Weilin, et al.
Publicado: (2020)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
por: Truong, Cao-Sang, et al.
Publicado: (2022)

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
por: Guo, Zong Sheng, et al.
Publicado: (2017)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation
por: Chen, Lingjuan, et al.
Publicado: (2021)

A Selectable and Excisable Marker System for the Rapid Creation of Recombinant Poxviruses
por: Rintoul, Julia L., et al.
Publicado: (2011)

Comparative Analysis of Viral Gene Expression Programs during Poxvirus Infection: A Transcriptional Map of the Vaccinia and Monkeypox Genomes
por: Rubins, Kathleen H., et al.
Publicado: (2008)

Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy
por: Liu, Weilin, et al.
Publicado: (2022)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus
por: Burgess, Hannah M., et al.
Publicado: (2018)

A Fatal Case of Nafcillin-Induced Hepatotoxicity: A Case Report and the Literature Review
por: Alam, Mian Bilal, et al.
Publicado: (2012)

Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus
por: Arndt, William D., et al.
Publicado: (2016)

Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
por: Kirn, David H, et al.
Publicado: (2007)

The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses
por: Pelin, Adrian, et al.
Publicado: (2018)

Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
por: Myers, Rachel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nadjspigmtpr0qp3c5ruii6joc